- call +1-201-465-4211
- email sales@mrinsights.biz
Oncology biosimilars are similar versions of oncology biologics that are manufactured by different companies and have been officially approved for cancer treatment. Biosimilars are cost-effective molecules with the same efficacy and potency as the original reference biologic. The relatively easy manufacturing of biosimilars and the license to manufacture biosimilars after the expiration of original reference biologic is acting in favor of the global oncology biosimilars market.
Scope of the Report:
This report focuses on the Oncology Biosimilars in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Cancer represents a massive burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of several cancer therapeutics has allowed the entry of biosimilars, which are being incorporated into oncology treatment practices. Biosimilars are synthesized with the use of biologic components such as monoclonal antibodies, proteins, hormones, nucleic acids, colony stimulating factors, interleukins, and enzymes. The market offers huge growth opportunities for vendors because of the growing incidence of cancer. The clinical pipeline for cancer biosimilars is vast, featuring candidates in different stages of development. Around 30% of all the biosimilars that are awaiting the US FDA’s approval are monoclonal antibodies, including biosimilars of Avastin, MabThera, and Herceptin.
Factors like the arrival of new biosimilars to drive market growth during the forecast period. Unlike generic drugs, which have APIs that are identical to original drugs, biosimilars are similar to their originator biologic compounds. Biosimilars developed by different manufacturers differ from the original product as well as from each other. Since they are less expensive than biologics, patients will be able to afford and access biosimilars more easily than biologics. Rise in number of patent expiries, increase in prevalence of cancer, growing aging population, promising drug pipeline, need for cost-effective treatment, favorable government regulations are some of the key drivers promoting the growth of oncology biosimilars market.
The worldwide market for Oncology Biosimilars is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Biocon
Celltrion
Dr Reddy's Laboratories
F Hoffmann-La Roche
Mylan
Sandoz
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Breast Cancer
Blood Cancer
Colorectal Cancer
Non-Small
Cell Lung Cancer
Neutropenia
Others
Market Segment by Applications, can be divided into
Retail Pharmacies
Hospitals
There are 15 Chapters to deeply display the global Oncology Biosimilars market.
Chapter 1, to describe Oncology Biosimilars Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Oncology Biosimilars, with sales, revenue, and price of Oncology Biosimilars, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Oncology Biosimilars, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Oncology Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Oncology Biosimilars sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Oncology Biosimilars Introduction
1.2 Market Analysis by Type
1.2.1 Breast Cancer
1.2.2 Blood Cancer
1.2.3 Colorectal Cancer
1.2.4 Non-Small
1.2.5 Cell Lung Cancer
1.2.6 Neutropenia
1.2.7 Others
1.3 Market Analysis by Applications
1.3.1 Retail Pharmacies
1.3.2 Hospitals
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Biocon
2.1.1 Business Overview
2.1.2 Oncology Biosimilars Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Biocon Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Celltrion
2.2.1 Business Overview
2.2.2 Oncology Biosimilars Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Celltrion Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Dr Reddy's Laboratories
2.3.1 Business Overview
2.3.2 Oncology Biosimilars Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Dr Reddy's Laboratories Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 F Hoffmann-La Roche
2.4.1 Business Overview
2.4.2 Oncology Biosimilars Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 F Hoffmann-La Roche Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Mylan
2.5.1 Business Overview
2.5.2 Oncology Biosimilars Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Mylan Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Sandoz
2.6.1 Business Overview
2.6.2 Oncology Biosimilars Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Sandoz Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Oncology Biosimilars Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Oncology Biosimilars Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Oncology Biosimilars Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Oncology Biosimilars Manufacturer Market Share in 2017
3.3.2 Top 6 Oncology Biosimilars Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Oncology Biosimilars Market Analysis by Regions
4.1 Global Oncology Biosimilars Sales, Revenue and Market Share by Regions
4.1.1 Global Oncology Biosimilars Sales and Market Share by Regions (2013-2018)
4.1.2 Global Oncology Biosimilars Revenue and Market Share by Regions (2013-2018)
4.2 North America Oncology Biosimilars Sales and Growth Rate (2013-2018)
4.3 Europe Oncology Biosimilars Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Oncology Biosimilars Sales and Growth Rate (2013-2018)
4.5 South America Oncology Biosimilars Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Oncology Biosimilars Sales and Growth Rate (2013-2018)
5 North America Oncology Biosimilars by Countries
5.1 North America Oncology Biosimilars Sales, Revenue and Market Share by Countries
5.1.1 North America Oncology Biosimilars Sales and Market Share by Countries (2013-2018)
5.1.2 North America Oncology Biosimilars Revenue and Market Share by Countries (2013-2018)
5.2 United States Oncology Biosimilars Sales and Growth Rate (2013-2018)
5.3 Canada Oncology Biosimilars Sales and Growth Rate (2013-2018)
5.4 Mexico Oncology Biosimilars Sales and Growth Rate (2013-2018)
6 Europe Oncology Biosimilars by Countries
6.1 Europe Oncology Biosimilars Sales, Revenue and Market Share by Countries
6.1.1 Europe Oncology Biosimilars Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Oncology Biosimilars Revenue and Market Share by Countries (2013-2018)
6.2 Germany Oncology Biosimilars Sales and Growth Rate (2013-2018)
6.3 UK Oncology Biosimilars Sales and Growth Rate (2013-2018)
6.4 France Oncology Biosimilars Sales and Growth Rate (2013-2018)
6.5 Russia Oncology Biosimilars Sales and Growth Rate (2013-2018)
6.6 Italy Oncology Biosimilars Sales and Growth Rate (2013-2018)
7 Asia-Pacific Oncology Biosimilars by Countries
7.1 Asia-Pacific Oncology Biosimilars Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Oncology Biosimilars Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Oncology Biosimilars Revenue and Market Share by Countries (2013-2018)
7.2 China Oncology Biosimilars Sales and Growth Rate (2013-2018)
7.3 Japan Oncology Biosimilars Sales and Growth Rate (2013-2018)
7.4 Korea Oncology Biosimilars Sales and Growth Rate (2013-2018)
7.5 India Oncology Biosimilars Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Oncology Biosimilars Sales and Growth Rate (2013-2018)
8 South America Oncology Biosimilars by Countries
8.1 South America Oncology Biosimilars Sales, Revenue and Market Share by Countries
8.1.1 South America Oncology Biosimilars Sales and Market Share by Countries (2013-2018)
8.1.2 South America Oncology Biosimilars Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Oncology Biosimilars Sales and Growth Rate (2013-2018)
8.3 Argentina Oncology Biosimilars Sales and Growth Rate (2013-2018)
8.4 Colombia Oncology Biosimilars Sales and Growth Rate (2013-2018)
9 Middle East and Africa Oncology Biosimilars by Countries
9.1 Middle East and Africa Oncology Biosimilars Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Oncology Biosimilars Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Oncology Biosimilars Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Oncology Biosimilars Sales and Growth Rate (2013-2018)
9.3 UAE Oncology Biosimilars Sales and Growth Rate (2013-2018)
9.4 Egypt Oncology Biosimilars Sales and Growth Rate (2013-2018)
9.5 Nigeria Oncology Biosimilars Sales and Growth Rate (2013-2018)
9.6 South Africa Oncology Biosimilars Sales and Growth Rate (2013-2018)
10 Global Oncology Biosimilars Market Segment by Type
10.1 Global Oncology Biosimilars Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Oncology Biosimilars Sales and Market Share by Type (2013-2018)
10.1.2 Global Oncology Biosimilars Revenue and Market Share by Type (2013-2018)
10.2 Breast Cancer Sales Growth and Price
10.2.1 Global Breast Cancer Sales Growth (2013-2018)
10.2.2 Global Breast Cancer Price (2013-2018)
10.3 Blood Cancer Sales Growth and Price
10.3.1 Global Blood Cancer Sales Growth (2013-2018)
10.3.2 Global Blood Cancer Price (2013-2018)
10.4 Colorectal Cancer Sales Growth and Price
10.4.1 Global Colorectal Cancer Sales Growth (2013-2018)
10.4.2 Global Colorectal Cancer Price (2013-2018)
10.5 Non-Small Sales Growth and Price
10.5.1 Global Non-Small Sales Growth (2013-2018)
10.5.2 Global Non-Small Price (2013-2018)
10.6 Cell Lung Cancer Sales Growth and Price
10.6.1 Global Cell Lung Cancer Sales Growth (2013-2018)
10.6.2 Global Cell Lung Cancer Price (2013-2018)
10.7 Neutropenia Sales Growth and Price
10.7.1 Global Neutropenia Sales Growth (2013-2018)
10.7.2 Global Neutropenia Price (2013-2018)
10.8 Others Sales Growth and Price
10.8.1 Global Others Sales Growth (2013-2018)
10.8.2 Global Others Price (2013-2018)
11 Global Oncology Biosimilars Market Segment by Application
11.1 Global Oncology Biosimilars Sales Market Share by Application (2013-2018)
11.2 Retail Pharmacies Sales Growth (2013-2018)
11.3 Hospitals Sales Growth (2013-2018)
12 Oncology Biosimilars Market Forecast (2018-2023)
12.1 Global Oncology Biosimilars Sales, Revenue and Growth Rate (2018-2023)
12.2 Oncology Biosimilars Market Forecast by Regions (2018-2023)
12.2.1 North America Oncology Biosimilars Market Forecast (2018-2023)
12.2.2 Europe Oncology Biosimilars Market Forecast (2018-2023)
12.2.3 Asia-Pacific Oncology Biosimilars Market Forecast (2018-2023)
12.2.4 South America Oncology Biosimilars Market Forecast (2018-2023)
12.2.5 Middle East and Africa Oncology Biosimilars Market Forecast (2018-2023)
12.3 Oncology Biosimilars Market Forecast by Type (2018-2023)
12.3.1 Global Oncology Biosimilars Sales Forecast by Type (2018-2023)
12.3.2 Global Oncology Biosimilars Market Share Forecast by Type (2018-2023)
12.4 Oncology Biosimilars Market Forecast by Application (2018-2023)
12.4.1 Global Oncology Biosimilars Sales Forecast by Application (2018-2023)
12.4.2 Global Oncology Biosimilars Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Oncology Biosimilars Picture
Table Product Specifications of Oncology Biosimilars
Figure Global Sales Market Share of Oncology Biosimilars by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
